Table 1.
1L treatment regimens (mutually exclusive).
| Treatment regimens | Patients treated with 1L treatment, n (%) (n = 1286) |
|---|---|
| All patients receiving PB-CT | 825 (64.2) |
| Cisplatin or carboplatin + gemcitabine | 304 (23.6) |
| Paclitaxel + carboplatin | 14 (1.1) |
| Paclitaxel + carboplatin + gemcitabine | 2 (0.2) |
| Oxaliplatin + gemcitabine | 2 (0.2) |
| Cisplatin or carboplatin (mono) | 12 (0.9) |
| Moderately complex and intensive block CT (OPS 8-543; MVAC or gemcitabine + cisplatin) | 491 (38.2) |
| All patients receiving IO† | 139 (10.8) |
| Atezolizumab | 21 (1.6) |
| Pembrolizumab | 71 (5.5) |
| Nivolumab‡ | 47 (3.7) |
| All patients receiving other non–PB-CT | 322 (25.0) |
| Gemcitabine | 79 (6.1) |
| Paclitaxel + gemcitabine | 10 (0.8) |
| Paclitaxel | 8 (0.6) |
| Docetaxel | 23 (1.8) |
| Vinflunine | 7 (0.5) |
| Vinflunine + gemcitabine | 6 (0.5) |
| Noncomplex CT (OPS 8-542; gemcitabine or paclitaxel + gemcitabine or paclitaxel) | 189 (14.7) |
†
IOs for use in the 1L and 2L settings were first approved in the European Union beginning in late 2017.
‡
During the patient inclusion period (2015–2019), nivolumab was not approved as a 1L IO and was only approved for use in the 2L setting in the European Union.
1L: First-line; 2L: Second-line; IO: Immunotherapy; mono: Monotherapy; MVAC: Methotrexate + vinblastine + doxorubicin + cisplatin; OPS: Operations and procedures key; PB-CT: Platinum-based chemotherapy.